 Michael Szarek
Concepts (294)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Coronary Syndrome | 35 | 2024 | 267 | 6.120 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 40 | 2025 | 430 | 5.300 |
Why?
| | Antibodies, Monoclonal, Humanized | 37 | 2025 | 759 | 4.160 |
Why?
| | Anticholesteremic Agents | 22 | 2024 | 150 | 4.050 |
Why?
| | Cholesterol, LDL | 39 | 2025 | 358 | 3.170 |
Why?
| | Lipoprotein(a) | 16 | 2025 | 67 | 3.100 |
Why?
| | Peripheral Arterial Disease | 14 | 2024 | 457 | 2.060 |
Why?
| | Glycosides | 8 | 2025 | 37 | 2.000 |
Why?
| | Heptanoic Acids | 20 | 2014 | 64 | 1.720 |
Why?
| | Cardiovascular Diseases | 23 | 2025 | 2004 | 1.720 |
Why?
| | Stroke | 14 | 2022 | 1071 | 1.690 |
Why?
| | Myocardial Infarction | 17 | 2024 | 1022 | 1.610 |
Why?
| | Pyrroles | 20 | 2014 | 202 | 1.600 |
Why?
| | Dyslipidemias | 8 | 2025 | 177 | 1.460 |
Why?
| | Ischemic Attack, Transient | 4 | 2020 | 60 | 1.430 |
Why?
| | Diabetes Mellitus, Type 2 | 15 | 2025 | 2441 | 1.260 |
Why?
| | Proprotein Convertase 9 | 14 | 2024 | 68 | 1.130 |
Why?
| | Treatment Outcome | 52 | 2025 | 10230 | 1.130 |
Why?
| | Eicosapentaenoic Acid | 2 | 2025 | 36 | 1.110 |
Why?
| | Platelet Aggregation Inhibitors | 10 | 2024 | 442 | 1.020 |
Why?
| | Angina, Unstable | 7 | 2019 | 76 | 1.010 |
Why?
| | Rivaroxaban | 12 | 2024 | 252 | 0.950 |
Why?
| | Brain Ischemia | 7 | 2022 | 321 | 0.940 |
Why?
| | Double-Blind Method | 29 | 2025 | 1876 | 0.930 |
Why?
| | Hypertriglyceridemia | 1 | 2024 | 39 | 0.870 |
Why?
| | Heart Failure | 7 | 2024 | 2150 | 0.780 |
Why?
| | Antibodies, Monoclonal | 5 | 2023 | 1367 | 0.770 |
Why?
| | Renal Insufficiency, Chronic | 6 | 2025 | 566 | 0.730 |
Why?
| | Humans | 109 | 2025 | 129650 | 0.660 |
Why?
| | Hypercholesterolemia | 7 | 2020 | 102 | 0.640 |
Why?
| | Aged | 57 | 2025 | 22103 | 0.620 |
Why?
| | Drug Therapy, Combination | 13 | 2024 | 1040 | 0.620 |
Why?
| | Carcinoma, Renal Cell | 1 | 2021 | 180 | 0.610 |
Why?
| | Lower Extremity | 8 | 2022 | 404 | 0.610 |
Why?
| | Middle Aged | 54 | 2025 | 31154 | 0.610 |
Why?
| | Patient Admission | 1 | 2019 | 182 | 0.580 |
Why?
| | Simvastatin | 4 | 2010 | 60 | 0.550 |
Why?
| | Kidney Neoplasms | 1 | 2021 | 350 | 0.530 |
Why?
| | Aspirin | 10 | 2024 | 380 | 0.490 |
Why?
| | Male | 66 | 2025 | 63681 | 0.480 |
Why?
| | Female | 65 | 2025 | 68776 | 0.460 |
Why?
| | Risk Factors | 19 | 2024 | 9765 | 0.460 |
Why?
| | Patient Readmission | 1 | 2019 | 667 | 0.440 |
Why?
| | Venous Thromboembolism | 3 | 2023 | 284 | 0.430 |
Why?
| | Global Health | 3 | 2021 | 329 | 0.430 |
Why?
| | Ischemia | 5 | 2022 | 406 | 0.410 |
Why?
| | Life Change Events | 1 | 2014 | 148 | 0.410 |
Why?
| | Secondary Prevention | 5 | 2019 | 218 | 0.400 |
Why?
| | Triglycerides | 3 | 2024 | 527 | 0.390 |
Why?
| | Serine Proteinase Inhibitors | 3 | 2024 | 43 | 0.380 |
Why?
| | Career Choice | 1 | 2014 | 207 | 0.380 |
Why?
| | Factor Xa Inhibitors | 6 | 2024 | 170 | 0.380 |
Why?
| | Markov Chains | 2 | 2010 | 117 | 0.370 |
Why?
| | Cholesterol | 3 | 2022 | 412 | 0.340 |
Why?
| | Risk Assessment | 8 | 2024 | 3240 | 0.330 |
Why?
| | Time Factors | 10 | 2024 | 6556 | 0.320 |
Why?
| | Students, Medical | 1 | 2014 | 316 | 0.320 |
Why?
| | Atherosclerosis | 2 | 2024 | 402 | 0.320 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2010 | 170 | 0.310 |
Why?
| | Apolipoproteins B | 6 | 2022 | 43 | 0.310 |
Why?
| | Coronary Disease | 5 | 2009 | 385 | 0.300 |
Why?
| | Vascular Surgical Procedures | 2 | 2021 | 294 | 0.300 |
Why?
| | Follow-Up Studies | 8 | 2023 | 4897 | 0.290 |
Why?
| | Biomarkers | 9 | 2025 | 3973 | 0.290 |
Why?
| | Endovascular Procedures | 2 | 2022 | 301 | 0.290 |
Why?
| | Albuminuria | 3 | 2024 | 183 | 0.260 |
Why?
| | Models, Statistical | 1 | 2010 | 623 | 0.260 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2024 | 1368 | 0.260 |
Why?
| | Cholesterol, HDL | 4 | 2019 | 205 | 0.260 |
Why?
| | Proportional Hazards Models | 9 | 2019 | 1201 | 0.250 |
Why?
| | Survival Analysis | 1 | 2008 | 1274 | 0.230 |
Why?
| | HIV-1 | 1 | 2010 | 836 | 0.230 |
Why?
| | Anticoagulants | 4 | 2023 | 637 | 0.230 |
Why?
| | Rosuvastatin Calcium | 2 | 2022 | 20 | 0.220 |
Why?
| | Hemorrhage | 6 | 2024 | 678 | 0.220 |
Why?
| | Internship and Residency | 1 | 2014 | 1053 | 0.220 |
Why?
| | Primary Health Care | 1 | 2014 | 1680 | 0.210 |
Why?
| | Glomerular Filtration Rate | 2 | 2024 | 711 | 0.210 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2023 | 82 | 0.200 |
Why?
| | Antifibrinolytic Agents | 1 | 2023 | 47 | 0.200 |
Why?
| | Hyperlipidemias | 1 | 2003 | 126 | 0.200 |
Why?
| | RNA, Small Interfering | 1 | 2024 | 587 | 0.200 |
Why?
| | Hospitalization | 6 | 2023 | 2070 | 0.190 |
Why?
| | Blood Coagulation Disorders | 1 | 2023 | 167 | 0.180 |
Why?
| | Muscles | 1 | 2022 | 322 | 0.180 |
Why?
| | Phenylurea Compounds | 1 | 2021 | 89 | 0.170 |
Why?
| | Cataract | 1 | 2023 | 208 | 0.170 |
Why?
| | Quinolines | 1 | 2021 | 156 | 0.170 |
Why?
| | Kidney Diseases | 1 | 2023 | 384 | 0.160 |
Why?
| | Renal Insufficiency | 1 | 2021 | 149 | 0.160 |
Why?
| | Health Status | 1 | 2024 | 755 | 0.160 |
Why?
| | Colonic Neoplasms | 1 | 2021 | 243 | 0.160 |
Why?
| | Patient Care Team | 1 | 2024 | 605 | 0.160 |
Why?
| | Lipids | 4 | 2010 | 625 | 0.150 |
Why?
| | Thrombosis | 1 | 2022 | 343 | 0.150 |
Why?
| | Multifactorial Inheritance | 1 | 2019 | 150 | 0.150 |
Why?
| | Liver X Receptors | 1 | 2018 | 31 | 0.150 |
Why?
| | Venous Thrombosis | 1 | 2020 | 176 | 0.150 |
Why?
| | Coronary Artery Bypass | 1 | 2019 | 224 | 0.140 |
Why?
| | Apolipoproteins E | 1 | 2018 | 77 | 0.140 |
Why?
| | Diabetes Complications | 1 | 2019 | 224 | 0.140 |
Why?
| | Atrial Fibrillation | 1 | 2022 | 376 | 0.140 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 569 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2021 | 2012 | 0.140 |
Why?
| | Neoplasms, Experimental | 1 | 2018 | 171 | 0.140 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2018 | 64 | 0.130 |
Why?
| | Prospective Studies | 8 | 2022 | 7133 | 0.130 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2023 | 3628 | 0.130 |
Why?
| | Myocardial Ischemia | 3 | 2007 | 258 | 0.130 |
Why?
| | HIV Infections | 1 | 2010 | 2720 | 0.120 |
Why?
| | Phospholipids | 2 | 2009 | 215 | 0.120 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2021 | 964 | 0.120 |
Why?
| | Hospital Mortality | 1 | 2019 | 850 | 0.120 |
Why?
| | Hypoglycemic Agents | 4 | 2024 | 1220 | 0.120 |
Why?
| | Immunotherapy, Adoptive | 1 | 2018 | 295 | 0.120 |
Why?
| | Killer Cells, Natural | 1 | 2018 | 427 | 0.120 |
Why?
| | Proprotein Convertases | 1 | 2014 | 15 | 0.110 |
Why?
| | Receptors, Interleukin-3 | 1 | 2014 | 5 | 0.110 |
Why?
| | C-Reactive Protein | 3 | 2022 | 401 | 0.110 |
Why?
| | Colorectal Neoplasms | 1 | 2021 | 752 | 0.110 |
Why?
| | Disease-Free Survival | 2 | 2018 | 648 | 0.110 |
Why?
| | Adult | 14 | 2023 | 35576 | 0.110 |
Why?
| | Antigens, Neoplasm | 2 | 2006 | 309 | 0.100 |
Why?
| | Coronary Artery Disease | 1 | 2019 | 679 | 0.100 |
Why?
| | Skin Neoplasms | 2 | 2014 | 825 | 0.100 |
Why?
| | Neoplasms | 2 | 2023 | 2470 | 0.100 |
Why?
| | Clinical Trials as Topic | 3 | 2008 | 1004 | 0.100 |
Why?
| | Hematologic Neoplasms | 1 | 2014 | 140 | 0.100 |
Why?
| | Clinical Decision-Making | 1 | 2015 | 303 | 0.100 |
Why?
| | Injections, Subcutaneous | 2 | 2024 | 147 | 0.100 |
Why?
| | Developing Countries | 1 | 2014 | 287 | 0.100 |
Why?
| | Immunity, Innate | 1 | 2018 | 804 | 0.090 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 1001 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 1 | 2014 | 643 | 0.090 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2018 | 592 | 0.090 |
Why?
| | Urban Population | 1 | 2014 | 441 | 0.090 |
Why?
| | Sodium-Glucose Transporter 1 | 2 | 2020 | 10 | 0.090 |
Why?
| | Heparin | 2 | 2023 | 253 | 0.090 |
Why?
| | Stroke Volume | 2 | 2024 | 592 | 0.090 |
Why?
| | Dendritic Cells | 1 | 2014 | 478 | 0.090 |
Why?
| | Bottle Feeding | 1 | 2010 | 21 | 0.090 |
Why?
| | Norway | 1 | 2010 | 42 | 0.090 |
Why?
| | Denmark | 1 | 2010 | 44 | 0.090 |
Why?
| | Netherlands | 1 | 2010 | 77 | 0.090 |
Why?
| | Finland | 1 | 2010 | 90 | 0.090 |
Why?
| | Serum Amyloid A Protein | 2 | 2007 | 31 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 2061 | 0.090 |
Why?
| | Sweden | 1 | 2010 | 93 | 0.090 |
Why?
| | Likelihood Functions | 1 | 2010 | 138 | 0.080 |
Why?
| | Arteries | 2 | 2022 | 265 | 0.080 |
Why?
| | Risk | 6 | 2008 | 854 | 0.080 |
Why?
| | Aged, 80 and over | 7 | 2020 | 7086 | 0.080 |
Why?
| | Probability | 1 | 2010 | 306 | 0.080 |
Why?
| | Myocardial Revascularization | 1 | 2009 | 72 | 0.080 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 422 | 0.080 |
Why?
| | Hydroxymethylglutaryl CoA Reductases | 1 | 2009 | 14 | 0.080 |
Why?
| | Biomarkers, Tumor | 2 | 2006 | 1181 | 0.080 |
Why?
| | Melanoma | 2 | 2006 | 730 | 0.080 |
Why?
| | Practice Guidelines as Topic | 3 | 2019 | 1501 | 0.080 |
Why?
| | United States Government Agencies | 1 | 2008 | 6 | 0.080 |
Why?
| | Inflammation | 4 | 2023 | 2736 | 0.070 |
Why?
| | Biometry | 1 | 2008 | 69 | 0.070 |
Why?
| | Postoperative Complications | 1 | 2019 | 2483 | 0.070 |
Why?
| | Tissue Plasminogen Activator | 2 | 2022 | 222 | 0.070 |
Why?
| | Cell Line, Tumor | 3 | 2021 | 3215 | 0.070 |
Why?
| | United States | 3 | 2019 | 13903 | 0.070 |
Why?
| | Counseling | 1 | 2010 | 385 | 0.070 |
Why?
| | Incidence | 3 | 2022 | 2644 | 0.070 |
Why?
| | Recurrence | 4 | 2019 | 1007 | 0.070 |
Why?
| | Decision Making | 1 | 2014 | 851 | 0.070 |
Why?
| | Breast Feeding | 1 | 2010 | 424 | 0.070 |
Why?
| | Fibrinolytic Agents | 2 | 2022 | 263 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2008 | 335 | 0.070 |
Why?
| | Reactive Oxygen Species | 1 | 2009 | 596 | 0.060 |
Why?
| | Acute Disease | 3 | 2021 | 980 | 0.060 |
Why?
| | Cancer Vaccines | 1 | 2006 | 164 | 0.060 |
Why?
| | Lipoproteins, HDL | 1 | 2005 | 85 | 0.060 |
Why?
| | Antigen-Antibody Complex | 1 | 2004 | 84 | 0.060 |
Why?
| | CD40 Ligand | 1 | 2004 | 38 | 0.060 |
Why?
| | Medication Adherence | 1 | 2009 | 558 | 0.060 |
Why?
| | Lipoproteins, LDL | 1 | 2004 | 127 | 0.060 |
Why?
| | Subtilisins | 1 | 2023 | 10 | 0.050 |
Why?
| | Thromboplastin | 1 | 2023 | 70 | 0.050 |
Why?
| | Ezetimibe | 1 | 2022 | 25 | 0.050 |
Why?
| | Creatine Kinase | 1 | 2022 | 73 | 0.050 |
Why?
| | Metabolic Syndrome | 1 | 2005 | 339 | 0.050 |
Why?
| | Numbers Needed To Treat | 1 | 2021 | 7 | 0.050 |
Why?
| | Plasma Membrane Neurotransmitter Transport Proteins | 1 | 2021 | 4 | 0.050 |
Why?
| | Pharmacogenomic Testing | 1 | 2022 | 61 | 0.050 |
Why?
| | Creatine | 1 | 2021 | 58 | 0.050 |
Why?
| | Inflammation Mediators | 1 | 2004 | 505 | 0.050 |
Why?
| | Goals | 1 | 2022 | 160 | 0.050 |
Why?
| | Receptors, Immunologic | 1 | 2022 | 216 | 0.040 |
Why?
| | Algorithms | 1 | 2008 | 1622 | 0.040 |
Why?
| | Membrane Transport Proteins | 1 | 2021 | 149 | 0.040 |
Why?
| | Diabetic Nephropathies | 1 | 2024 | 284 | 0.040 |
Why?
| | Disease Progression | 2 | 2024 | 2635 | 0.040 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 259 | 0.040 |
Why?
| | Mycoses | 1 | 2020 | 71 | 0.040 |
Why?
| | Ventricular Function, Left | 1 | 2023 | 527 | 0.040 |
Why?
| | Odds Ratio | 3 | 2009 | 1023 | 0.040 |
Why?
| | Mice, Nude | 1 | 2021 | 683 | 0.040 |
Why?
| | Diarrhea | 1 | 2020 | 180 | 0.040 |
Why?
| | Hypotension | 1 | 2020 | 116 | 0.040 |
Why?
| | Antigens, CD | 1 | 2022 | 489 | 0.040 |
Why?
| | Age Factors | 1 | 2007 | 3144 | 0.040 |
Why?
| | Propensity Score | 1 | 2021 | 265 | 0.040 |
Why?
| | Placebo Effect | 1 | 2019 | 55 | 0.040 |
Why?
| | Patient Education as Topic | 1 | 2024 | 743 | 0.040 |
Why?
| | Sex Characteristics | 1 | 2024 | 737 | 0.040 |
Why?
| | Sex Factors | 1 | 2024 | 1968 | 0.040 |
Why?
| | Diabetic Ketoacidosis | 1 | 2020 | 197 | 0.040 |
Why?
| | Transplantation, Haploidentical | 1 | 2018 | 21 | 0.040 |
Why?
| | American Heart Association | 1 | 2019 | 296 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2021 | 570 | 0.040 |
Why?
| | Cell Count | 1 | 2018 | 314 | 0.030 |
Why?
| | Mice, SCID | 1 | 2018 | 351 | 0.030 |
Why?
| | Erythrocytes | 1 | 2022 | 672 | 0.030 |
Why?
| | Cohort Studies | 2 | 2022 | 5420 | 0.030 |
Why?
| | Infant | 1 | 2010 | 9024 | 0.030 |
Why?
| | Muscular Diseases | 2 | 2008 | 107 | 0.030 |
Why?
| | Liver | 1 | 2024 | 1839 | 0.030 |
Why?
| | Vascular Diseases | 1 | 2019 | 241 | 0.030 |
Why?
| | Kidney | 1 | 2024 | 1385 | 0.030 |
Why?
| | Morbidity | 1 | 2017 | 302 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2018 | 588 | 0.030 |
Why?
| | Apolipoproteins | 2 | 2007 | 38 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2022 | 1119 | 0.030 |
Why?
| | Immunoglobulin M | 2 | 2009 | 275 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2022 | 1333 | 0.030 |
Why?
| | Cytoplasm | 2 | 2006 | 263 | 0.030 |
Why?
| | Tissue Donors | 1 | 2018 | 391 | 0.030 |
Why?
| | Cause of Death | 1 | 2017 | 393 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2018 | 814 | 0.030 |
Why?
| | Fluorobenzenes | 1 | 2014 | 15 | 0.030 |
Why?
| | Interleukin-3 | 1 | 2014 | 23 | 0.030 |
Why?
| | Syndrome | 2 | 2007 | 341 | 0.030 |
Why?
| | Thrombolytic Therapy | 1 | 2015 | 137 | 0.030 |
Why?
| | Diphtheria Toxin | 1 | 2014 | 64 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2021 | 2391 | 0.030 |
Why?
| | Serine Endopeptidases | 1 | 2014 | 118 | 0.030 |
Why?
| | Oxidation-Reduction | 2 | 2009 | 1033 | 0.030 |
Why?
| | Multivariate Analysis | 2 | 2007 | 1502 | 0.030 |
Why?
| | Acute Kidney Injury | 1 | 2020 | 790 | 0.030 |
Why?
| | Prognosis | 3 | 2005 | 3794 | 0.030 |
Why?
| | Mice | 2 | 2021 | 16937 | 0.030 |
Why?
| | Quality of Life | 1 | 2024 | 2704 | 0.030 |
Why?
| | Immunoglobulin G | 2 | 2009 | 847 | 0.030 |
Why?
| | Child, Preschool | 2 | 2005 | 10517 | 0.020 |
Why?
| | Neoplasm Staging | 2 | 2006 | 1295 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 857 | 0.020 |
Why?
| | Interleukin-6 | 2 | 2007 | 720 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2014 | 390 | 0.020 |
Why?
| | Adolescent | 3 | 2006 | 20393 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2018 | 2871 | 0.020 |
Why?
| | Pyrimidines | 1 | 2014 | 459 | 0.020 |
Why?
| | Predictive Value of Tests | 2 | 2006 | 1952 | 0.020 |
Why?
| | Sulfonamides | 1 | 2014 | 496 | 0.020 |
Why?
| | Mutation | 1 | 2021 | 3717 | 0.020 |
Why?
| | Pilot Projects | 1 | 2015 | 1587 | 0.020 |
Why?
| | Autoantibodies | 2 | 2009 | 1466 | 0.020 |
Why?
| | Ireland | 1 | 2008 | 27 | 0.020 |
Why?
| | Apolipoprotein A-I | 1 | 2008 | 28 | 0.020 |
Why?
| | Europe | 1 | 2009 | 364 | 0.020 |
Why?
| | Thromboembolism | 1 | 2009 | 112 | 0.020 |
Why?
| | Lipoproteins | 1 | 2009 | 171 | 0.020 |
Why?
| | United Kingdom | 1 | 2008 | 257 | 0.020 |
Why?
| | Animals | 2 | 2021 | 35361 | 0.020 |
Why?
| | Child | 2 | 2005 | 20883 | 0.020 |
Why?
| | Drug Prescriptions | 1 | 2009 | 248 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2015 | 2742 | 0.020 |
Why?
| | Cerebral Infarction | 1 | 2006 | 42 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2008 | 198 | 0.020 |
Why?
| | ROC Curve | 1 | 2007 | 503 | 0.020 |
Why?
| | Hematuria | 1 | 2005 | 12 | 0.020 |
Why?
| | Immunotherapy, Active | 1 | 2005 | 9 | 0.020 |
Why?
| | Cerebral Hemorrhage | 1 | 2006 | 107 | 0.020 |
Why?
| | Aspartate Aminotransferases | 1 | 2005 | 88 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2005 | 153 | 0.010 |
Why?
| | Apolipoprotein B-100 | 1 | 2004 | 10 | 0.010 |
Why?
| | Drug Utilization | 1 | 2005 | 171 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2007 | 769 | 0.010 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2005 | 132 | 0.010 |
Why?
| | Arteriosclerosis | 1 | 2004 | 88 | 0.010 |
Why?
| | Angina Pectoris | 1 | 2004 | 67 | 0.010 |
Why?
| | Solubility | 1 | 2004 | 235 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 833 | 0.010 |
Why?
| | Troponin | 1 | 2003 | 50 | 0.010 |
Why?
| | Research Design | 1 | 2009 | 1044 | 0.010 |
Why?
| | Databases, Factual | 1 | 2008 | 1269 | 0.010 |
Why?
| | Heart Arrest | 1 | 2004 | 321 | 0.010 |
Why?
| | Pain | 1 | 2005 | 789 | 0.010 |
Why?
| | Retrospective Studies | 2 | 2007 | 14518 | 0.010 |
Why?
| | Brain | 1 | 2007 | 2679 | 0.010 |
Why?
|
|
Szarek's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|